Intrinsic value of WAVE Life Sciences - WVE

Previous Close

$38.31

  Intrinsic Value

$1.19

stock screener

  Rating & Target

str. sell

-97%

Previous close

$38.31

 
Intrinsic value

$1.19

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of WVE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  6
  9
  14
  20
  28
  39
  52
  68
  87
  110
  137
  168
  202
  240
  283
  329
  379
  432
  490
  551
  615
  683
  754
  828
  906
  987
  1,071
  1,159
  1,250
  1,345
Variable operating expenses, $m
  117
  181
  270
  392
  554
  761
  1,022
  1,341
  1,726
  2,180
  2,707
  3,310
  3,990
  4,747
  5,581
  6,493
  7,479
  8,539
  9,671
  10,873
  12,143
  13,481
  14,886
  16,356
  17,891
  19,492
  21,159
  22,894
  24,697
  26,572
Fixed operating expenses, $m
  30
  30
  31
  32
  32
  33
  34
  35
  35
  36
  37
  38
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  55
  56
Total operating expenses, $m
  147
  211
  301
  424
  586
  794
  1,056
  1,376
  1,761
  2,216
  2,744
  3,348
  4,028
  4,786
  5,621
  6,534
  7,521
  8,582
  9,715
  10,918
  12,189
  13,528
  14,934
  16,405
  17,941
  19,543
  21,211
  22,947
  24,752
  26,628
Operating income, $m
  -141
  -202
  -288
  -404
  -558
  -756
  -1,004
  -1,308
  -1,674
  -2,106
  -2,607
  -3,180
  -3,826
  -4,546
  -5,339
  -6,205
  -7,142
  -8,149
  -9,225
  -10,367
  -11,574
  -12,846
  -14,180
  -15,576
  -17,035
  -18,556
  -20,140
  -21,788
  -23,501
  -25,282
EBITDA, $m
  -138
  -197
  -280
  -393
  -543
  -735
  -976
  -1,271
  -1,627
  -2,046
  -2,533
  -3,089
  -3,717
  -4,416
  -5,186
  -6,027
  -6,937
  -7,915
  -8,960
  -10,069
  -11,242
  -12,476
  -13,772
  -15,128
  -16,545
  -18,022
  -19,560
  -21,160
  -22,824
  -24,554
Interest expense (income), $m
  0
  0
  1
  3
  5
  9
  14
  20
  27
  36
  47
  60
  75
  93
  112
  134
  158
  184
  212
  243
  275
  309
  346
  384
  424
  467
  511
  557
  604
  654
  706
Earnings before tax, $m
  -141
  -203
  -291
  -410
  -567
  -769
  -1,023
  -1,335
  -1,710
  -2,153
  -2,667
  -3,255
  -3,919
  -4,658
  -5,473
  -6,363
  -7,326
  -8,362
  -9,467
  -10,642
  -11,884
  -13,191
  -14,564
  -16,001
  -17,502
  -19,067
  -20,696
  -22,392
  -24,155
  -25,988
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -141
  -203
  -291
  -410
  -567
  -769
  -1,023
  -1,335
  -1,710
  -2,153
  -2,667
  -3,255
  -3,919
  -4,658
  -5,473
  -6,363
  -7,326
  -8,362
  -9,467
  -10,642
  -11,884
  -13,191
  -14,564
  -16,001
  -17,502
  -19,067
  -20,696
  -22,392
  -24,155
  -25,988

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  85
  131
  196
  284
  400
  551
  739
  970
  1,249
  1,577
  1,958
  2,394
  2,886
  3,434
  4,037
  4,696
  5,410
  6,176
  6,995
  7,865
  8,784
  9,751
  10,767
  11,830
  12,941
  14,099
  15,305
  16,560
  17,864
  19,220
Adjusted assets (=assets-cash), $m
  85
  131
  196
  284
  400
  551
  739
  970
  1,249
  1,577
  1,958
  2,394
  2,886
  3,434
  4,037
  4,696
  5,410
  6,176
  6,995
  7,865
  8,784
  9,751
  10,767
  11,830
  12,941
  14,099
  15,305
  16,560
  17,864
  19,220
Revenue / Adjusted assets
  0.071
  0.069
  0.071
  0.070
  0.070
  0.071
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
  0.070
Average production assets, $m
  27
  41
  62
  89
  126
  173
  232
  305
  393
  496
  616
  753
  908
  1,080
  1,270
  1,477
  1,701
  1,943
  2,200
  2,473
  2,763
  3,067
  3,386
  3,721
  4,070
  4,434
  4,814
  5,208
  5,618
  6,045
Working capital, $m
  -15
  -23
  -35
  -51
  -71
  -98
  -132
  -173
  -223
  -281
  -349
  -427
  -515
  -612
  -720
  -838
  -965
  -1,102
  -1,248
  -1,403
  -1,567
  -1,739
  -1,920
  -2,110
  -2,308
  -2,515
  -2,730
  -2,954
  -3,186
  -3,428
Total debt, $m
  20
  54
  101
  166
  252
  362
  500
  670
  874
  1,115
  1,395
  1,715
  2,076
  2,478
  2,921
  3,405
  3,929
  4,491
  5,092
  5,730
  6,405
  7,115
  7,861
  8,641
  9,456
  10,306
  11,192
  12,113
  13,070
  14,065
Total liabilities, $m
  62
  96
  144
  208
  294
  404
  542
  712
  916
  1,158
  1,437
  1,757
  2,118
  2,520
  2,963
  3,447
  3,971
  4,533
  5,134
  5,773
  6,447
  7,158
  7,903
  8,684
  9,499
  10,349
  11,234
  12,155
  13,112
  14,108
Total equity, $m
  23
  35
  52
  75
  107
  146
  197
  258
  332
  419
  521
  637
  768
  913
  1,074
  1,249
  1,439
  1,643
  1,861
  2,092
  2,336
  2,594
  2,864
  3,147
  3,442
  3,750
  4,071
  4,405
  4,752
  5,113
Total liabilities and equity, $m
  85
  131
  196
  283
  401
  550
  739
  970
  1,248
  1,577
  1,958
  2,394
  2,886
  3,433
  4,037
  4,696
  5,410
  6,176
  6,995
  7,865
  8,783
  9,752
  10,767
  11,831
  12,941
  14,099
  15,305
  16,560
  17,864
  19,221
Debt-to-equity ratio
  0.890
  1.550
  1.950
  2.200
  2.360
  2.470
  2.540
  2.600
  2.630
  2.660
  2.680
  2.690
  2.700
  2.710
  2.720
  2.730
  2.730
  2.730
  2.740
  2.740
  2.740
  2.740
  2.740
  2.750
  2.750
  2.750
  2.750
  2.750
  2.750
  2.750
Adjusted equity ratio
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266
  0.266

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -141
  -203
  -291
  -410
  -567
  -769
  -1,023
  -1,335
  -1,710
  -2,153
  -2,667
  -3,255
  -3,919
  -4,658
  -5,473
  -6,363
  -7,326
  -8,362
  -9,467
  -10,642
  -11,884
  -13,191
  -14,564
  -16,001
  -17,502
  -19,067
  -20,696
  -22,392
  -24,155
  -25,988
Depreciation, amort., depletion, $m
  3
  5
  7
  11
  15
  21
  28
  37
  47
  60
  74
  91
  109
  130
  153
  178
  205
  234
  265
  298
  333
  370
  408
  448
  490
  534
  580
  627
  677
  728
Funds from operations, $m
  -138
  -198
  -283
  -399
  -552
  -748
  -995
  -1,298
  -1,663
  -2,093
  -2,593
  -3,165
  -3,809
  -4,528
  -5,320
  -6,185
  -7,121
  -8,128
  -9,202
  -10,344
  -11,551
  -12,822
  -14,156
  -15,552
  -17,011
  -18,532
  -20,116
  -21,765
  -23,479
  -25,260
Change in working capital, $m
  -6
  -8
  -12
  -16
  -21
  -27
  -34
  -41
  -50
  -59
  -68
  -78
  -88
  -98
  -108
  -118
  -127
  -137
  -146
  -155
  -164
  -173
  -181
  -190
  -198
  -207
  -215
  -224
  -233
  -242
Cash from operations, $m
  -132
  -190
  -272
  -383
  -531
  -722
  -962
  -1,257
  -1,613
  -2,035
  -2,525
  -3,087
  -3,722
  -4,430
  -5,212
  -6,067
  -6,994
  -7,991
  -9,056
  -10,189
  -11,387
  -12,649
  -13,975
  -15,363
  -16,813
  -18,326
  -19,901
  -21,541
  -23,246
  -25,018
Maintenance CAPEX, $m
  -2
  -3
  -5
  -7
  -11
  -15
  -21
  -28
  -37
  -47
  -60
  -74
  -91
  -109
  -130
  -153
  -178
  -205
  -234
  -265
  -298
  -333
  -370
  -408
  -448
  -490
  -534
  -580
  -627
  -677
New CAPEX, $m
  -9
  -15
  -20
  -28
  -37
  -47
  -59
  -73
  -88
  -103
  -120
  -137
  -155
  -172
  -190
  -207
  -224
  -241
  -257
  -273
  -289
  -304
  -319
  -334
  -349
  -364
  -379
  -395
  -410
  -426
Cash from investing activities, $m
  -11
  -18
  -25
  -35
  -48
  -62
  -80
  -101
  -125
  -150
  -180
  -211
  -246
  -281
  -320
  -360
  -402
  -446
  -491
  -538
  -587
  -637
  -689
  -742
  -797
  -854
  -913
  -975
  -1,037
  -1,103
Free cash flow, $m
  -143
  -208
  -297
  -418
  -578
  -784
  -1,042
  -1,358
  -1,737
  -2,185
  -2,705
  -3,298
  -3,967
  -4,712
  -5,532
  -6,427
  -7,396
  -8,437
  -9,548
  -10,727
  -11,974
  -13,287
  -14,664
  -16,105
  -17,611
  -19,180
  -20,815
  -22,516
  -24,284
  -26,121
Issuance/(repayment) of debt, $m
  20
  34
  48
  65
  86
  110
  138
  170
  204
  241
  280
  320
  361
  402
  443
  484
  524
  563
  601
  638
  675
  710
  746
  780
  815
  850
  885
  921
  958
  995
Issuance/(repurchase) of shares, $m
  148
  215
  308
  433
  598
  809
  1,073
  1,397
  1,784
  2,240
  2,769
  3,371
  4,049
  4,804
  5,633
  6,538
  7,516
  8,565
  9,685
  10,873
  12,128
  13,449
  14,834
  16,284
  17,797
  19,375
  21,017
  22,726
  24,502
  26,349
Cash from financing (excl. dividends), $m  
  168
  249
  356
  498
  684
  919
  1,211
  1,567
  1,988
  2,481
  3,049
  3,691
  4,410
  5,206
  6,076
  7,022
  8,040
  9,128
  10,286
  11,511
  12,803
  14,159
  15,580
  17,064
  18,612
  20,225
  21,902
  23,647
  25,460
  27,344
Total cash flow (excl. dividends), $m
  26
  42
  58
  80
  105
  135
  170
  209
  251
  296
  344
  393
  443
  494
  544
  594
  643
  691
  738
  784
  829
  873
  916
  959
  1,001
  1,044
  1,087
  1,131
  1,176
  1,223
Retained Cash Flow (-), $m
  -148
  -215
  -308
  -433
  -598
  -809
  -1,073
  -1,397
  -1,784
  -2,240
  -2,769
  -3,371
  -4,049
  -4,804
  -5,633
  -6,538
  -7,516
  -8,565
  -9,685
  -10,873
  -12,128
  -13,449
  -14,834
  -16,284
  -17,797
  -19,375
  -21,017
  -22,726
  -24,502
  -26,349
Prev. year cash balance distribution, $m
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  2
  -174
  -249
  -354
  -493
  -674
  -903
  -1,188
  -1,533
  -1,944
  -2,425
  -2,978
  -3,606
  -4,310
  -5,089
  -5,944
  -6,873
  -7,874
  -8,947
  -10,089
  -11,299
  -12,576
  -13,918
  -15,325
  -16,796
  -18,330
  -19,930
  -21,595
  -23,326
  -25,126
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  1
  -159
  -217
  -291
  -382
  -489
  -610
  -743
  -881
  -1,019
  -1,152
  -1,271
  -1,371
  -1,447
  -1,494
  -1,510
  -1,495
  -1,450
  -1,378
  -1,282
  -1,169
  -1,043
  -912
  -781
  -653
  -535
  -428
  -334
  -255
  -189
Current shareholders' claim on cash, %
  45.4
  20.7
  9.9
  4.9
  2.4
  1.3
  0.7
  0.3
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

FINANCIAL RATIOS  of  WAVE Life Sciences (WVE)

Valuation Ratios
P/E Ratio -16.4
Price to Sales 900.3
Price to Book 6.3
Price to Tangible Book
Price to Cash Flow -28.1
Price to Free Cash Flow -23.7
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 200%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -33.3%
Ret/ On Assets - 3 Yr. Avg. -85.3%
Return On Total Capital -36.2%
Ret/ On T. Cap. - 3 Yr. Avg. -103.2%
Return On Equity -36.2%
Return On Equity - 3 Yr. Avg. 35.7%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -5400%
EBITDA Margin - 3 Yr. Avg. -1800%
Operating Margin -5600%
Oper. Margin - 3 Yr. Avg. -1866.7%
Pre-Tax Margin -5500%
Pre-Tax Margin - 3 Yr. Avg. -1833.3%
Net Profit Margin -5500%
Net Profit Margin - 3 Yr. Avg. -1833.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

WVE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the WVE stock intrinsic value calculation we used $3.704 million for the last fiscal year's total revenue generated by WAVE Life Sciences. The default revenue input number comes from 0001 income statement of WAVE Life Sciences. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our WVE stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for WVE is calculated based on our internal credit rating of WAVE Life Sciences, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of WAVE Life Sciences.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of WVE stock the variable cost ratio is equal to 1975%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $29 million in the base year in the intrinsic value calculation for WVE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for WAVE Life Sciences.

Corporate tax rate of 27% is the nominal tax rate for WAVE Life Sciences. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the WVE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for WVE are equal to 449.3%.

Life of production assets of 8.3 years is the average useful life of capital assets used in WAVE Life Sciences operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for WVE is equal to -254.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $139.61 million for WAVE Life Sciences - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 29.32 million for WAVE Life Sciences is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of WAVE Life Sciences at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
IONS Ionis Pharmace 50.06 6.10  str.sell
PRAN Prana Biotechn 1.75 0.51  str.sell
PTCT PTC Therapeuti 31.71 214.00  str.buy
SRPT Sarepta Therap 111.99 2.96  str.sell
CELG Celgene 69.63 340.31  str.buy
TEVA Teva Pharmaceu 22.67 40.23  str.buy
PFE Pfizer 42.91 34.10  hold

COMPANY NEWS

▶ Wave Life Sciences: 3Q Earnings Snapshot   [07:49AM  Associated Press]
▶ Wave Life Sciences: 2Q Earnings Snapshot   [08:33AM  Associated Press]
▶ Top Growth Stocks This Week   [May-11-18 12:02PM  Simply Wall St.]
▶ Wave Life Sciences: 1Q Earnings Snapshot   [May-09-18 09:04AM  Associated Press]
▶ Why It's So Dang Hard to Value Biotech Deals   [Mar-21-18 03:43PM  Motley Fool]
▶ 3 Biotech Stocks That Soared: Are They Buys?   [Nov-18-17 05:47PM  Motley Fool]
▶ Wave Life Sciences reports 3Q loss   [Nov-09-17 08:06AM  Associated Press]
▶ Wave Life Sciences reports 2Q loss   [Aug-09-17 01:22PM  Associated Press]
▶ Wave Life Sciences reports 1Q loss   [May-10-17 08:12AM  Associated Press]
▶ WAVE Life Sciences 2017 Pipeline Update   [04:35PM  Business Wire]
▶ Heres Why These Five Stocks Are Trading Higher Today   [Sep-22-16 01:35PM  at Insider Monkey]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.